{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:51:19Z","timestamp":1791514279598,"version":"4.3.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"EISAI Italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Alzheimer\u2019s disease (AD) poses a growing clinical and organizational challenge, requiring coordinated, multidisciplinary care models. In Italy, significant regional variability in resources and access to diagnostic services persists, while the implementation of community-based care models, the expanding role of biomarkers, and the advent of disease-modifying therapies (DMTs) further highlight the need for a more coordinated and equitable dementia care network.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Develop system-level recommendations to optimise the organisation of AD care delivery in Italy in anticipation of DMTs introduction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using the RAND\/UCLA Appropriateness Method, a multidisciplinary panel rated 55 statements across nine domains, evaluating appropriateness in two rounds and priority of implementation in a third round.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consensus was achieved for all statements, with high appropriateness and priority ratings. The statements outline a regional, network-based model organised across territorial services, Spoke and Hub centres, with formal governance responsible for pathway definition and monitoring. Referral pathways from primary care are based on cognitive and frailty assessment, with non-frail patients referred to Spoke for clinical, neuropsychological and neuroradiological evaluation. Patients potentially eligible for DMTs are referred to Hub centres, where diagnostic confirmation is completed and multidisciplinary teams assess treatment eligibility. When authorised, Hub centres are responsible for DMTs prescription and administration. The statements emphasise the need for standardised neuropsychological and neuroradiological protocols for amyloid-related imaging abnormalities (ARIA) monitoring, alongside the progressive adoption of plasma biomarkers, telemedicine, and structured communication with patients and caregivers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This consensus provides a pragmatic framework to support the reorganisation of AD care in Italy, ensuring that every patient is directed to the most appropriate level of care across a flexible regional network.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10072-026-09452-z","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:28:56Z","timestamp":1791512936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Organizing healthcare delivery in the era of disease-modifying therapies for Alzheimer\u2019s Disease: an Italian RAND\/UCLA consensus"],"prefix":"10.1007","volume":"47","author":[{"given":"Alessandro","family":"Padovani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Altini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Bellelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bozzali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ovidio","family":"Brignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annachiara","family":"Cagnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuele","family":"Iannacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Lodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giancarlo","family":"Logroscino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Marra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Nicora","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7096-3549","authenticated-orcid":false,"given":"Simone","family":"Parretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Spadin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Zappia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,9]]},"reference":[{"key":"9452_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1474043","volume":"11","author":"S Safiri","year":"2024","unstructured":"Safiri S, Ghaffari Jolfayi A, Fazlollahi A, Morsali S, Sarkesh A, Daei Sorkhabi A et al (2024) Alzheimer\u2019s disease: a comprehensive review of epidemiology, risk factors, symptoms diagnosis, management, caregiving, advanced treatments and associated challenges. Front Med 11:1474043. https:\/\/doi.org\/10.3389\/fmed.2024.1474043","journal-title":"Front Med"},{"issue":"14","key":"9452_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26146980","volume":"26","author":"N Scarano","year":"2025","unstructured":"Scarano N, Musumeci F, Casini B, Brullo C, D\u2019Ursi P, Fossa P et al (2025) Alzheimer\u2019s disease etiology hypotheses and therapeutic strategies: a perspective. Int J Mol Sci 26(14):6980. https:\/\/doi.org\/10.3390\/ijms26146980","journal-title":"Int J Mol Sci"},{"key":"9452_CR3","unstructured":"Alzheimer Europe. The Prevalence of Dementia in Europe 2025 [Internet]. 2025. Available from: https:\/\/www.alzheimer-europe.org\/sites\/default\/files\/2026-01\/Alzheimer%20Europe%20-%20Dementia%20Prevalence%20Report%202025%20-%20FINAL%20-%20Digital.pdf. Accessed 10 Jun 2026"},{"key":"9452_CR4","unstructured":"Ministero della Salute. Dati epidemiologici [Internet]. 2023 Sep 20. Available from: https:\/\/www.salute.gov.it\/new\/it\/tema\/demenze\/dati-epidemiologici\/"},{"issue":"1","key":"9452_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-025-12735-4","volume":"25","author":"FS Mennini","year":"2025","unstructured":"Mennini FS, Sciattella P, Scortichini M, Migliorini R, Trabucco Aurilio M, Marcellusi A et al (2025) Burden of disease of Alzheimer disease in Italy: a real-world data analysis. BMC Health Serv Res 25(1):588. https:\/\/doi.org\/10.1186\/s12913-025-12735-4","journal-title":"BMC Health Serv Res"},{"key":"9452_CR6","unstructured":"Istituto Superiore di Sanit\u00e0. Diagnosi e trattamento di demenza e Mild Cognitive Impairment [Internet]. 2024. Available from: https:\/\/www.iss.it\/documents\/20126\/9140509\/LG+Demenza+e+MCI_v3.0.pdf\/45961ff0-aa16-5017-1244-8426403600ec?t=1707121203312. Accessed 10 Jun 2026"},{"key":"9452_CR7","unstructured":"AIMA - Associazione italiana malattia di Alzheimer, SIN -Societ\u00e0 Italiana di Neurologia. 7 BUONI MOTIVI E 7 BUONE PROPOSTE PER NON DIMENTICARE L\u2019ALZHEIMER [Internet]. 2021. Available from: https:\/\/alzheimer-aima.it\/documenti\/202109%20-%20AIMA%20e%20SIN_7%20BUONI%20MOTIVI.pdf. Accessed 10 Jun 2026"},{"key":"9452_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102595","volume":"103","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Chen J, Li Y, Jiao B, Luo S (2025) Disease-modifying therapies for Alzheimer\u2019s disease: clinical trial progress and opportunity. Ageing Res Rev 103:102595. https:\/\/doi.org\/10.1016\/j.arr.2024.102595","journal-title":"Ageing Res Rev"},{"key":"9452_CR9","unstructured":"Commission Implementing Decision of 15.4.2025 concerning the implementation of conditions or restrictions set out in Article 127a of Directive 2001\/83\/EC of the European Parliament and of the Council concerning a marketing authorisation for \u2018LEQEMBI - Lecanemab\u2019, a medicinal product for human use [Internet]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250415164783\/dec_164783_en.pdf"},{"key":"9452_CR10","unstructured":"Commission Implementing Decision of 24.9.2025 concerning the implementation of conditions or restrictions set out in Article 127a of Directive 2001\/83\/EC of the European Parliament and of the Council concerning a marketing authorisation for \u2018Kisunla - donanemab\u2019, a medicinal product for human use [Internet]. Available from: https:\/\/ec.europa.eu\/health\/documents\/community-register\/2025\/20250924167378\/dec_167378_en.pdf"},{"key":"9452_CR11","unstructured":"Committee for Medicinal Products for Human Use (CHMP). Assessment report - Leqembi [Internet]. 2024 Nov. Report EMA\/CHMP\/573107\/2024. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/leqembi-epar-public-assessment-report_en.pdf"},{"issue":"9","key":"9452_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/jpm15090437","volume":"15","author":"AE Alkhalifa","year":"2025","unstructured":"Alkhalifa AE, Al Mokhlf A, Ali H, Al-Ghraiybah NF, Syropoulou V (2025) Anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: evidence, ARIA risk, and precision patient selection. J Pers Med 15(9):437. https:\/\/doi.org\/10.3390\/jpm15090437","journal-title":"J Pers Med"},{"issue":"S8","key":"9452_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/alz.095319","volume":"20","author":"O Hansson","year":"2024","unstructured":"Hansson O, Whitson H, Edelmayer RM, Allen LA, Galasko DR, Karikari TK et al (2024) Evidence-based clinical practice guideline on the use of blood-based biomarkers in Alzheimer\u2019s Disease: presentation of preliminary evidence, and opportunity for public comment. Alzheim Dement 20(S8):e095319. https:\/\/doi.org\/10.1002\/alz.095319","journal-title":"Alzheim Dement"},{"key":"9452_CR14","unstructured":"Ministero Della Salute. Decreto 23 maggio 2022, n. 77 [Internet]. Gazzetta Ufficiale. Available from: https:\/\/www.gazzettaufficiale.it\/eli\/id\/2022\/06\/22\/22G00085\/SG. Accessed 10 Jun 2026"},{"issue":"6","key":"9452_CR15","doi-asserted-by":"publisher","first-page":"3159","DOI":"10.1007\/s00415-023-11642-0","volume":"270","author":"M Filippi","year":"2023","unstructured":"Filippi M, Cecchetti G, Cagnin A, Marra C, Nobili F, Parnetti L et al (2023) Redefinition of dementia care in Italy in the era of amyloid-lowering agents for the treatment of Alzheimer\u2019s disease: an expert opinion and practical guideline. J Neurol 270(6):3159\u20133170. https:\/\/doi.org\/10.1007\/s00415-023-11642-0","journal-title":"J Neurol"},{"issue":"2","key":"9452_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s10072-023-06958-8","volume":"45","author":"I Bacigalupo","year":"2024","unstructured":"Bacigalupo I, Giaquinto F, Salvi E, Carnevale G, Vaccaro R, Matascioli F et al (2024) A new national survey of centers for cognitive disorders and dementias in Italy. Neurol Sci 45(2):525\u2013538. https:\/\/doi.org\/10.1007\/s10072-023-06958-8","journal-title":"Neurol Sci"},{"key":"9452_CR17","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, Burnand B, LaCalle JR, Lazaro P et al The RAND\/UCLA Appropriateness Method User\u2019s Manual [Internet]. Available from: https:\/\/www.rand.org\/pubs\/authors\/k\/kahan_james_p.html. Accessed 01 Dec 2025"},{"issue":"12","key":"9452_CR18","doi-asserted-by":"publisher","first-page":"6875","DOI":"10.1007\/s10072-025-08576-y","volume":"46","author":"A Benussi","year":"2025","unstructured":"Benussi A, Agosta F, Alfano AR, Antico A, Bellelli G, Bonanni L et al (2025) Italian intersocietal recommendations for restructuring the diagnostic-therapeutic pathway for the implementation and appropriate use of anti-amyloid monoclonal antibodies in Alzheimer\u2019s disease. Neurol Sci 46(12):6875\u20136894. https:\/\/doi.org\/10.1007\/s10072-025-08576-y","journal-title":"Neurol Sci"},{"issue":"7","key":"9452_CR19","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1007\/s10072-025-08143-5","volume":"46","author":"C Marra","year":"2025","unstructured":"Marra C, Beccia F, Caffarra P, L\u2019Abbate F, Agosta F, Benussi A et al (2025) Towards a new Value-based scenario for the management of dementia in Italy: a SINdem delphi consensus study. Neurol Sci 46(7):2913\u20132923. https:\/\/doi.org\/10.1007\/s10072-025-08143-5","journal-title":"Neurol Sci"},{"issue":"1","key":"9452_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s40134-025-00435-0","volume":"13","author":"M Chiara","year":"2025","unstructured":"Chiara M, Francesca T, Andrea R, Domenico S, Marco R, Barbara G et al (2025) MRI in the clinical management of Alzheimer\u2019s disease: from early detection to therapy guidance. Curr Radiol Rep 13(1):4. https:\/\/doi.org\/10.1007\/s40134-025-00435-0","journal-title":"Curr Radiol Rep"},{"issue":"3","key":"9452_CR21","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1159\/000545799","volume":"25","author":"A Felbecker","year":"2025","unstructured":"Felbecker A, Rouaud O, Lathuiliere A, Allali G, Sollberger M, Meyer-Heim T et al (2025) Anti-amyloid monoclonal antibodies for the treatment of Alzheimer disease: intersocietal recommendations for their appropriate use in Switzerland. Neurodegener Dis 25(3):114\u2013125. https:\/\/doi.org\/10.1159\/000545799","journal-title":"Neurodegener Dis"},{"issue":"1","key":"9452_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3174\/ajnr.A8469","volume":"46","author":"PM Cogswell","year":"2025","unstructured":"Cogswell PM, Andrews TJ, Barakos JA, Barkhof F, Bash S, Benayoun MD et al (2025) Alzheimer disease anti-amyloid immunotherapies: imaging recommendations and practice considerations for monitoring of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol 46(1):24\u201332. https:\/\/doi.org\/10.3174\/ajnr.A8469","journal-title":"AJNR Am J Neuroradiol"},{"issue":"8","key":"9452_CR23","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheim Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheim Dement"},{"issue":"11","key":"9452_CR24","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s43587-024-00731-y","volume":"4","author":"J Therriault","year":"2024","unstructured":"Therriault J, Janelidze S, Benedet AL, Ashton NJ, Arranz Mart\u00ednez J, Gonzalez-Escalante A et al (2024) Diagnosis of Alzheimer\u2019s disease using plasma biomarkers adjusted to clinical probability. Nat Aging 4(11):1529\u20131537. https:\/\/doi.org\/10.1038\/s43587-024-00731-y","journal-title":"Nat Aging"},{"issue":"3","key":"9452_CR25","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/S1474-4422(23)00447-7","volume":"23","author":"GB Frisoni","year":"2024","unstructured":"Frisoni GB, Festari C, Massa F, Cotta Ramusino M, Orini S, Aarsland D et al (2024) European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol 23(3):302\u2013312. https:\/\/doi.org\/10.1016\/S1474-4422(23)00447-7","journal-title":"Lancet Neurol"},{"issue":"2","key":"9452_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70116","volume":"17","author":"G Giacomucci","year":"2025","unstructured":"Giacomucci G, Crucitti C, Ingannato A, Moschini V, Bagnoli S, Pozzi FE et al (2025) The two cut-offs approach for plasma p-tau217 in detecting Alzheimer\u2019s disease in subjective cognitive decline and mild cognitive impairment. Alzheimers Dement (Amst) 17(2):e70116. https:\/\/doi.org\/10.1002\/dad2.70116","journal-title":"Alzheimers Dement (Amst)"},{"issue":"12","key":"9452_CR27","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1093\/brain\/awae292","volume":"147","author":"G Koch","year":"2024","unstructured":"Koch G, Altomare D, Benussi A, Br\u00e9chet L, Casula EP, Dodich A et al (2024) The emerging field of non-invasive brain stimulation in Alzheimer\u2019s disease. Brain 147(12):4003\u20134016. https:\/\/doi.org\/10.1093\/brain\/awae292","journal-title":"Brain"},{"issue":"6","key":"9452_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70337","volume":"21","author":"A Antonioni","year":"2025","unstructured":"Antonioni A, Martorana A, Santarnecchi E, Hampel H, Koch G (2025) The neurobiological foundation of effective repetitive transcranial magnetic brain stimulation in Alzheimer\u2019s disease. Alzheim Dement 21(6):e70337. https:\/\/doi.org\/10.1002\/alz.70337","journal-title":"Alzheim Dement"},{"issue":"1","key":"9452_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13195-025-01709-7","volume":"17","author":"G Koch","year":"2025","unstructured":"Koch G, Casula EP, Bonn\u00ec S, Borghi I, Assogna M, Di Lorenzo F et al (2025) Effects of 52 weeks of precuneus rTMS in Alzheimer\u2019s disease patients: a randomized trial. Alzheim Res Ther 17(1):69. https:\/\/doi.org\/10.1186\/s13195-025-01709-7","journal-title":"Alzheim Res Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09452-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09452-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:28:59Z","timestamp":1791512939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-026-09452-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["9452"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09452-z","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"14 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Ethical approval and informed consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Alessandro Padovani has received speaker honoraria from Lilly, Eisai, AbbVie, Lusofarmaco, and Pfizer; has served on national and international advisory boards for Lilly, Lundbeck, Roche, Lusofarmaco, Novo Nordisk, and Biogen; and has acted as principal investigator in clinical studies sponsored by PrimusAD, Roche, Biogen, and Novo Nordisk; Mattina Altini has nothing to disclose; Giuseppe Bellelli has received speaker and advisory board honoraria from Eisai, Eli-Lilly, PIAM, Neopharmed, Gentili, Damor; Marco Bozzali has received speaker honoraria from Eli-Lilly, Eisai, Biogen, PIAM, Neopharmed Gentili, Siemens; received compensation for consulting services from EISAI and GE Healthcare; took part in Advisory Boards for Eli-Lilly, Roche, Novo Nordisk; Ovidio Brignoli has nothing to disclose; Annachiara Cagnin has received speaker and advisrory board honoraria from Eisai, Eli-Lilly, Novo nordisk, PIAM, Neopharmed Gentili, GE-Healthcare; Antonio Cherubini has received speaker and advisory board honoraria from Eisai, Italfarmaco; Manuele Iannacci has nothing to disclose; Raffaele Lodi has nothing to disclose; Giancarlo Logroscino has served as investigator for clinical trials sponsored by Biogen Pharmaceuticals, Axovant, Alector, Denali, Roche, Eisai, Genentech, Amylyx, PIAM Farmaceutici SpA; he has served as a consultant and has given Lectures for EISAI, Roche, Lilly, Piam Farmaceutici Spa, Biogen, Denovo Nordisk; Camillo Marra is a member of the Dementia National Board and participates in the drafting of the new National Dementia Plan. He is a member of the EAN Panel on Dementia. He has received research support funds from the Ministry of Health, AIFA, EU commission Horizon Program, EU Joint Programme \u2013 Neurodegenerative Disease Research (JPND), PROMIS. Speaker at sponsored conferences for Eisai, Biogen, Eli Lilly, Novonordisk, Angelini, Roche, Piam, Lundbeck, Neopharmed, Consultant exopert in working groups for Biogen, Eisai, Eli Lilly, Novonordisk, Neopharmed, Piam; Patrizia Spadin has nothing to disclose; Carlo Nicora has nothing to disclose; Mario Zappia has received speaker fees and consultancy honoraria from Arteventi Management, Gas Communication, Full Congress Eventi, Sole Blu Sicilia, Sanitanova, Thenewway, OCM Comunicazioni, Zambon, Universit\u00e0 Cattolica del Sacro Cuore, Fondazione SIN, Centro Organizzazione Congressi, UVET, OPT S.p.A., SIN, IQVIA, HAVAS PR Milan S.r.l., Altems Advisory S.r.l., Aristea International S.r.l., Lundbeck Italia S.p.A., and MED POINT S.r.l.; Simone Parretti, Anna Sacco: IQVIA employment; IQVIA received professional service fees from Eisai Italia.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"850"}}